• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom dips after hours on Q1 EPS miss, remains confident of U.S. G7 launch this year

April 28, 2022 By Sean Whooley

Dexcom updated logoDexcom (Nasdaq:DXCM) shares took a hit after hours today on first-quarter results that fell short of the consensus earnings forecast.

DXCM shares were down 6.2% after hours but mostly recovered by the end of the next day.

The San Diego-based company posted profits of $97.3 million, or 93¢ per share, on sales of $628.8 million for the three months ended March 31, 2022, for a 72.2% bottom-line gain on sales growth of 24.5%.

Adjusted to exclude one-time items, earnings per share were 32¢, 20¢ behind expectations on Wall Street, where analysts were looking for sales of $623.36.

Highlights for Dexcom in the first quarter of 2022 included winning CE mark approval for its next-generation G7 CGM, launching the Dexcom One platform in the United Kingdom and garnering FDA breakthrough device designation for the use of CGMs in hospitals.

“Dexcom is off to a great start in 2022, advancing a number of strategic initiatives that strengthen our foundation for long-term growth,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “We are very excited about our initial launch of G7 internationally and look forward to bringing this product to many more people globally over the course of the year.”

Dexcom remains unmoved on its financial guidance for 2022, saying it expects revenues to range between $2.82 billion and $2.94 billion. That would represent growth of between 15% and 20% year-over-year.

In the company’s earnings call, as transcribed by The Motley Fool, Sayer said the company is confident in “a meaningful U.S. launch of G7 this year,” with the next-generation platform still under FDA 510(k) review. He said the company expects clearance to come after the American Diabetes Association’s Scientific Sessions from June 3–7, 2022.

Sayer noted that Dexcom’s teams are preparing for a seamless transition once the G7 is available in the U.S., with preliminary discussions with payers to drive market access and the addition of incremental G7 lines in advance of the loss to support the expected ramp in demand.

The company is also working with insulin delivery partners to ensure that connected pumps and pens are integrated with the newest G7 technology.

“Our plan is to extend the G7 launch to a steady cadence of additional international markets over the remainder of 2022 with a growing impact to our overall sensor mix in the second half of the year,” Sayer said. “In the U.S., our 510(k) submission for the G7 sensor, receiver and Android and iOS apps remain under review. We are in the traditional back and forth that comes with these processes. And we appreciate the FDA’s ongoing attention to their view even as they juggle a very busy schedule.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Dexcom

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS